Prostate Cancer Articles

Search for New Prostate Cancer Targets Yields a Profusion of Options
Despite the introduction of novel therapies over the past decade, advanced prostate cancer remains an incurable disease in need of new strategies to overcome drug resistance.
Sipuleucel-T (Provenge) was associated with a median overall survival of 47.7 months in a subgroup of patients with asymptomatic or minimally invasive metastatic castration-resistant prostate cancer.
Tracers Increase PET Imaging Sensitivity in Prostate Cancer
Manoj K. Jain, MD, discusses new imaging modalities and what they could mean for the field going forward.
Research Initiative Comparing Proton Therapy With IMRT in Prostate Cancer
Randal Henderson, MD, MBA, discusses the data that led to the PCORI-funded trial, what the results could mean for the field, and interesting research on the horizon.
Armamentarium Continues to Evolve Across Metastatic Prostate Cancer
Manish Kohli, MD, discusses the agents that have redefined the treatment paradigm of metastatic prostate cancer and details ongoing work to elucidate genomic classifiers.
FDA Grants Enzalutamide Priority Review for Metastatic Hormone-Sensitive Prostate Cancer
The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.
Investigators Assess PARP Inhibitor-Abiraterone Combo as Frontline mCRPC Therapy
Seeking to explore an apparent synergy between agents, investigators are evaluating the PARP inhibitor olaparib in combination with the hormone blocker abiraterone in men with metastatic castration-resistant prostate cancer who have received no prior cytotoxic chemotherapy or new hormonal agents.
Winston Tan, MD, discusses the influx of treatment options in nonmetastatic castration-resistant prostate cancer and the modalities that are being used in an effort to ensure their optimal use.
Vogelzang Highlights Decades of Innovation in Prostate Cancer
Nicholas J. Vogelzang, MD, FASCO, FACP, discusses groundbreaking developments that have transformed the treatment of prostate cancer, as well as current issues in urology.
Sipuleucel-T received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy.
Publication Bottom Border
Border Publication